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SUMMARY
Background
Human complement factor H (CFH), a central complement control protein, is a member of the regulators of complement activation family. Recent studies suggested that CFH may play a key role in resistance of complement mediated lysis in various cancer cells. In this study, we investigated the role of CFH in human lung cancer.
Methods
Expression of CFH in lung cancer cells was analyzed by RT-PCR, western blotting, and immunofluorescence. Binding of CFH to lung cancer cells was detected by flow cytometry. In primary lung tumors, the protein expression of CFH was evaluated by IHC on tissue microarray.
Results
We found, mRNA expression of CFH was detected in six out of ten NSCLC cell lines, but not in SCLC cell lines. Consistence with the western blotting result, immunofluorescence analysis demonstrated CFH protein expression in three NSCLC cell lines, and the immunoreaction was mainly associated with cell cytoplasm and membrane. In primary lung tumors, 54 out of 101 samples exhibited high expression of CFH, and high expression was significantly correlated with lung adenocarcinoma (p=0.009). Also, in ADC of lung, Kaplan-Meier survival analysis showed a tendency that CFH-positive tumors had worse prognosis in comparison to CFHnegative tumors (p=0.082). Additionally, shorter survival time of patients with ADC (less than 20 months) was associated with higher protein expression of CFH (p=0.033).
Conclusion
Our data showed that non-small cell lung cancer cells expressed and secreted CFH. CFH might be a novel diagnostic marker for human lung adenocarcinoma. 
INTRODUCTION
Classification of lung cancer
Lung cancer is the leading cause of cancer-related death worldwide (Jemal et al, 2008) , and only 15% of all lung cancer patients are alive 5 years or more after diagnosis. (Komaki et al, 2000) .
Adenocarcinomas (ADCs) tend to be located in the periphery of the lung and originate preferentially from precursor cells of the mono-or bilayer surface epithelium of the lung periphery. Among people who have never smoked ("never-smokers"), ADC is the most common form of lung cancer (Subramanian et al, 2007) . A subtype of ADC, the bronchioloalveolar carcinoma, is more common in female never-smokers, and may have different responses to treatment (Raz et al, 2006 
Lung cancer and its biomarkers
In patients with suspected lung cancer, a clear and definite diagnosis is essential for the treatment strategy (Pio et al, 2010) . Late diagnosis is a fundamental obstacle to improving lung cancer outcomes (Carney, 2002; Chute et al, 1999) . Therefore, early detection of lung cancer is obviously the only way to improve the overall survival. Some diagnostic tools including CT scans, bronchoscopy, and sputum analysis are routinely used at clinics, but none of them turns out to be effective in early diagnosis of lung cancer. There were 512948 publications from 'Pubmed' associated with biomarkers, and 14123 publications were associated with lung cancer biomarkers till the end of 2010. Only p63 and CK5/6 are widely used as diagnostic markers for SCC of lung, while thyroid transcription factor-1 (TTF -1) together with CK7 is considered as a marker for lung ADC. In some cases, even in combination with these markers, SCC and ADC still could not be distinguished from each other. Given the fact that early detection of lung cancer at stage IA can raise the 5-year survival rate from the overall 15% to 80% (Mulshine, 2005) , reliable biomarkers for early diagnosis and survival prediction are increasingly in demand (Minna and Mangelsdorf, 1997; Hirsch et al, 2002 ).
Complement system and regulation of complement activity 10
The complement system is an integral part of the innate immune system. It consists of a number of small proteins found in the blood, generally synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). There are three biochemical pathways that activate the complement system: the classical pathway, the alternative pathway, and the lectin pathway. When the complement system is stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavage. The result of the activation cascade is massive amplification of the response and activation of the cell-killing membrane receptors. The complement system can be extremely effective in destroying pathogens, but can be equally damaging to self-tissue.
Complement regulation occurs predominantly at two steps within the complement cascade, the level of the convertase enzymes and of the membrane attack complex (MAC) (Liszewski et al, 1996) (Fig. 1) . 
Complement factor H (CFH)
4.1 The CFH gene family and CFH structure CFH is the best characterized protein of the CFH gene family, members of which belong to the regulators of complement activation family of proteins (Fig 2) . CFH is a 154 kDa plasma protein, soluble glycoprotein that circulates in human plasma at a concentration of 235-810 μg/ml (Saunders et al, 2006) . The family includes the complement regulators CFH and CFH-11 like protein 1 (CFHL1), as well as five CFH-related proteins CFHR1-5 (Jozsi and Zipfel, 2008) . CFHL1 proteins share complement regulatory functions with CFH and interact with heparin. The functions of CFH-related proteins (CFHR1 to CFHR5) are not well defined.
CFHR1, CFHR2 and CFHR4 are constituents of lipoproteins, while CFHR3 is known to interact with heparin (Zipfel et al, 2002; Skerka et al, 1997; Hellwage et al, 1999) . 
Function of CFH
CFH binds to C3b, accelerates the decay of the alternative pathway C3-convertase (C3bBb), and acts as a cofactor for the factor I-mediated proteolytic inactivation of C3b (Fig 3) (Rodriguez de Cordoba et al, 2004) . Evidence supporting the involvement of CFH in carcinogenesis is accumulating. For instance, malignant glioblastoma cells produce CFH and CFHL-1 (Gasque et al, 1996; Junnikkala et al, 2000) . Secretion of soluble complement inhibitor CFH and CFHL-1 by ovarian tumor cells could protect tumor cells against humoral immune attack and posed an obstacle for therapy with monoclonal antibodies (Junnikkala et al, 2002) . Similarly, in colon and lung cancer, the possible role of CFH was resistance to complement attack (Wilczek et al, 2008; Ajona et al, 2004 ). Additionally, CFH or related 13 proteins were considered as diagnostic markers for transitional cell cancer of the bladder (Kinders et al, 1998) . 
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AIMS OF THE STUDY
The aims of the study were: 
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DISCUSSION
The major findings present in the current study can be summarized as follows: 1) CFH was expressed in the majority of non-small cell lung cancer cell lines, 2) CFH was not expressed in small cell lung cancer cell lines, 3) cancer cells bound CFH to their surface, 4) the majority of tumor samples (53.5%) exhibited CFH positive staining, 5) CFH could be a biomarker for ADC of lung.
Expression of CFH in lung cancer cells
CFH is known as the most prominent fluid-phase complement inhibitor being present in plasma. It performs several activities which ultimately inhibit the alternative complement pathway. CFH was expressed in various malignant cell lines including ovarian, colon, bladder, liver, and lung cancer cell lines (Wilczek et al, 2008; Junnikkala et al, 2000; Cheng et al, 2005; Schlaf et al, 2002; Ajona et al, 2007) . CFH binds to C3b and acts as a cofactor for the factor I-mediated proteolytic inactivation of C3b (Pangburn et al, 1977) , while competing with factor B in binding to C3b to form the alternative pathway C3-convertase C3bBb (Whaley and Ruddy, 1976) . It also accelerates the decay of C3bBb. By inhibiting alternative complement activity, factor H also protects tumor cells against immune attack (Rodriguez de Cordoba et al, 2004; Gasque et al, 1992) . Earlier studies showed that, CFH is a marker for transitional cell cancer of the bladder (Kinders et al, 1998) and the utility of CFH as a diagnostic marker raised the question whether it could be a marker for other malignancies.
In our study, we analysed the mRNA and protein expression of CFH in a panel of lung cancer cell lines by RT-PCR, western blotting, flow cytometry, and immunofluorescence analysis. It turned out that several human NSCLC cells constitutively expressed and secreted CFH, while in SCLC cells, no CFH expression was detectable. These results are in line with previous report by Ajona et al (Ajona et al, 2004) , who reported that neither SCLC nor carcinoid cell lines expressed CFH, suggesting a phenotypic correlation between the expression of CFH and the neuroendocrine differentiation of the tumors. We further analyzed the ability of factor H binding to lung cancer cells. It turned out that factor H binding to the cell surface is independent on its expression in tumor cells.
Expression of CFH in lung tumor tissues
In the survey of protein expression of CFH in 101 primary lung tumors, we found that more than half of the samples (53.5%) showed CFH positive staining, while the other tumor samples were negatively stained, indicating that high expression of CFH is not an infrequent feature of this type of cancer. We could only divide the primary tumors into two major subgroups of ADC and SCC for statistical analysis, since the sample size of SCLC and LCLC was too small to be further evaluated. Although expression of CFH was not significantly associated with tumor progression, differentiation, and lymph node metastasis, it was significantly higher in ADCs (35/53) than in SCCs (16/41) (p<0.01). So far, the protein expression of CFH has only been evaluated in patients with primary colon adenocarcinoma by Wilczek et al. They found that CFH was expressed in both primary colon adenocarcinoma and metastatic foci in liver (Wilczek et al, 2008) . It is not yet clear if overexpression of CFH is a common event in adenocarcinoma, nevertheless, the result suggests that CFH could be a novel marker to distinguish NSCLC from SCLC and may particularly identify lung adenocarcinoma.
Clinical usefulness of CFH in human lung cancer
It has been reported that some human NSCLC cell lines highly expressing CFH or CFH-like protein are more susceptible to complement-mediated damage and more efficiently deposited C3b on the cell surface when they are blocked by specific anti-factor H antibodies (Ajona et al, 2004) . Tumor cells that express and bind CFH to their surface can prevent C3b accumulation upon their cell membranes leading to resistance of these cells to complementmediated lysis (Ajona et al, 2004) . Based on these characteristics, we supposed that tumors with high expression of CFH could be more aggressive and have a worse clinical outcome.
To test this hypothesis, we analysed the effect of CFH expression on patient survival.
Again, in ADC of lung, there was a tendency that CFH positive-tumors had a worse clinical outcome compared to CFH negative-tumors, although it did not reach statistical significance.
Interestingly, patients with ADC who had positive expression of CFH ended with a shorter survival time (less than 20 months). Evidence is not sufficient to prove the role of CFH as a prognostic marker in ADC of lung. Future studies with more tumor samples are needed to warrant the prognostic role of CFH in lung cancer; and we also plan to perform a prospective trial to detect the concentration of CFH in blood from lung cancer patients and healthy donors, to further investigate the clinical usefulness of CFH in human lung cancer.
Additionally, in line with the previous observations that CFH binds to apoptotic and necrotic cells (Leffler et al, 2010; Mihlan et al, 2009) , we found that apoptotic cells expressed more CFH compared to non-apoptotic cells of primary lung cancer. Most apoptotic cells do not undergo complement-mediated lysis probably due to the overexpression of CFH, which
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compensates the loss of m-C-Reg, a membrane-bound complement regulatory protein, and protect against excessive complement activation and lysis (Trouw et al, 2007) .
Immunotherapy is an attractive approach that, by design, is cancer specific and can target disseminated disease with minimal impact on normal tissues (Hirschowitz and Yannelli, 2009 
